Vanguard Group’s Cardlytics CDLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $3M | Buy |
260,979
+20,835
| +9% | +$322K | ﹤0.01% | 3430 |
|
|
2025
Q3 | $5.84M | Sell |
240,144
-1,547
| -0.6% | -$25.8K | ﹤0.01% | 3222 |
|
|
2025
Q2 | $3.98M | Sell |
241,691
-25,122
| -9% | -$434K | ﹤0.01% | 3291 |
|
|
2025
Q1 | $4.86M | Sell |
266,813
-2,331
| -0.9% | -$66.6K | ﹤0.01% | 3182 |
|
|
2024
Q4 | $9.99M | Buy |
269,144
+2,262
| +0.8% | +$86.6K | ﹤0.01% | 2959 |
|
|
2024
Q3 | $8.54M | Buy |
266,882
+25,627
| +11% | +$1.42M | ﹤0.01% | 3036 |
|
|
2024
Q2 | $19.8M | Buy |
241,255
+20,095
| +9% | +$2.17M | ﹤0.01% | 2573 |
|
|
2024
Q1 | $32M | Buy |
221,160
+5,781
| +3% | +$488K | ﹤0.01% | 2363 |
|
|
2023
Q4 | $19.8M | Buy |
215,379
+14,208
| +7% | +$1.44M | ﹤0.01% | 2600 |
|
|
2023
Q3 | $33.2M | Buy |
201,171
+23,131
| +13% | +$3.01M | ﹤0.01% | 2328 |
|
|
2023
Q2 | $11.3M | Buy |
178,040
+190
| +0.1% | +$11.5K | ﹤0.01% | 2872 |
|
|
2023
Q1 | $6.04M | Sell |
177,850
-61,426
| -26% | -$3.21M | ﹤0.01% | 3215 |
|
|
2022
Q4 | $13.8M | Sell |
239,276
-61,965
| -21% | -$3.83M | ﹤0.01% | 2815 |
|
|
2022
Q3 | $28.3M | Buy |
301,241
+5,356
| +2% | +$762K | ﹤0.01% | 2472 |
|
|
2022
Q2 | $66M | Buy |
295,885
+3,041
| +1% | +$1.02M | ﹤0.01% | 2061 |
|
|
2022
Q1 | $161M | Buy |
292,844
+2,340
| +0.8% | +$1.41M | ﹤0.01% | 1680 |
|
|
2021
Q4 | $192M | Buy |
290,504
+2,023
| +0.7% | +$1.55M | ﹤0.01% | 1634 |
|
|
2021
Q3 | $242M | Buy |
288,481
+2,325
| +0.8% | +$2.36M | 0.01% | 1486 |
|
|
2021
Q2 | $363M | Buy |
286,156
+12,705
| +5% | +$14.3M | 0.01% | 1211 |
|
|
2021
Q1 | $300M | Buy |
273,451
+89,777
| +49% | +$119M | 0.01% | 1310 |
|
|
2020
Q4 | $262M | Buy |
183,674
+50,480
| +38% | +$53.8M | 0.01% | 1301 |
|
|
2020
Q3 | $94M | Buy |
133,194
+4,851
| +4% | +$3.53M | ﹤0.01% | 1714 |
|
|
2020
Q2 | $89.8M | Buy |
128,343
+21,235
| +20% | +$12.3M | ﹤0.01% | 1731 |
|
|
2020
Q1 | $37.4M | Buy |
107,108
+2,828
| +3% | +$2M | ﹤0.01% | 1994 |
|
|
2019
Q4 | $65.5M | Buy |
104,280
+7,933
| +8% | +$3.88M | ﹤0.01% | 1966 |
|
|
2019
Q3 | $32.3M | Buy |
96,347
+20,834
| +28% | +$6.68M | ﹤0.01% | 2268 |
|
|
2019
Q2 | $19.6M | Buy |
75,513
+23,821
| +46% | +$4.77M | ﹤0.01% | 2520 |
|
|
2019
Q1 | $8.55M | Buy |
51,692
+1,934
| +4% | +$315K | ﹤0.01% | 2910 |
|
|
2018
Q4 | $5.39M | Buy |
49,758
+9,238
| +23% | +$1.56M | ﹤0.01% | 3059 |
|
|
2018
Q3 | $10.1M | Buy |
40,520
+13,822
| +52% | +$2.97M | ﹤0.01% | 2911 |
|
|
2018
Q2 | $5.81M | Buy |
26,698
+8,334
| +45% | +$1.54M | ﹤0.01% | 3158 |
|
|
2018
Q1 | $2.69M | Buy |
+18,364
| New | +$3.11M | ﹤0.01% | 3359 |
|
Other funds holding CDLX
CIP
6CM
KGAMU
WPM
RC
Vanguard Group's CDLX Position: Q4 2025 in Review
Vanguard Group increased its Cardlytics (CDLX) stake by 8.7% in Q4 2025, buying an estimated $322K and bringing the position to 260,979 shares worth $3M. The position accounts for ﹤0.01% of the portfolio, ranked #3430.
Vanguard Group first reported a position in CDLX in Q1 2018 and has held it in 32 quarters since. The position peaked at $363M in Q2 2021. 70 funds tracked by Wall St. Rank hold CDLX as of Q4 2025.
- Vanguard Group held 260,979 shares of Cardlytics worth $3M as of Q4 2025.
- Vanguard Group bought 20,835 Cardlytics shares in Q4 2025, an estimated $322K.
- Cardlytics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3430 holding.
- Vanguard Group first reported a position in Cardlytics in Q1 2018 and has held it in 32 quarters since.
- Vanguard Group's Cardlytics position peaked at $363M in Q2 2021.
- 70 funds tracked by Wall St. Rank held Cardlytics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.